Medicine ❯Gene Therapy ❯CRISPR

Casgevy

Sickle-cell Disease Beta-thalassaemia Clinical Trials Side Effects Approval Process Cost and Accessibility International Approval Process Manufacturing and Distribution β-thalassaemia

26 ARTICLES

last yr.

UK Approves World's First CRISPR-Based Treatment for Blood Disorders

The groundbreaking gene-editing therapy, Casgevy, offers a potential cure for sickle cell disease and beta thalassemia, but concerns about accessibility and safety remain.